Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

About this update from Immuneering Corporation

Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endpoint of overall survival, anticipated in mid-2028 NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that the first patient has been dosed in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer patients. Atebimetinib is a novel MEK inhibitor with a pulsatile mechanism designed to target RAS, RAF, and other MAPK pathway-driven cancers with greater durability and tolerability than traditional chronic inhibitors. “Pancreatic cancer remains a challenging malignancy to treat,” said Eileen M. O’Reilly, MD, FASCO, Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center, and the lead principal investigator of the MAPKeeper 301 study. “There is an urgent need for new first-line treatment options that can improve treatment outcomes by augmenting survival and improving quality of life. The MAPKeeper 301 trial evaluating atebimetinib with standard of care therapy represents an exciting step toward addressing that need.” The global MAPKeeper 301 trial (NCT07562152) is evaluating the safety and efficacy of atebimetinib + mGnP in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received no prior systemic anti-cancer therapy. Patients are being randomized to receive either atebimetinib + mGnP, or standard GnP treatment alone. The primary endpoint is overall survival (OS) of patients in the atebimetinib + mGnP arm versus patients in the GnP arm. Key secondary endpoints include progression free survival (PFS), overall response rate (ORR), disease control rate (DCR), safety and tolerability, and quality of life. “The dosing of the first patient in our pivotal Phase 3 trial is a significant milestone for Immuneering and, more importantly, patients with pancreatic cancer and their families,” said Ben Zeskind, PhD, CEO of Immuneering. “Global interest in MAPKeeper-301 has been overwhelming, largely driven by our highly en...

View stock analysis, news, and events for Immuneering Corporation